Efficacy and Safety of Modified Yupingfeng Nasal Spray in Controlling the Recurrence of Persistent and Moderate-Severe Allergic Rhinitis: Study Protocol for a Multicenter, Open-Label, Randomized, and Parallel-Arm Trial

Table 2

Study inclusion and exclusion criteria.

Inclusion criteria	• Patients who meet the above diagnostic standards
	• Patients with a positive skin prick test (SPT) of HDM of grade 2 or above
	• Patients between 18 and 65 years regardless of gender
	• Patients who have not received any medication for AR in the past two weeks
	• Patients who agree to participate in this study and sign the informed consent form (S3)
Exclusion criteria	• Patients combined with severe nasal septal deviation, chronic nasal-sinusitis, bronchial asthma, nasal polyps, and other diseases
	• Patients with heart, liver, and kidney disorders or autoimmune diseases
	• Patients with mental illnesses, mental disorders, and/or unable to cooperate well enough to complete the study
	• Patients during pregnancy, lactation, or pregnancy preparation
	• Patients who are allergic to the composition of the trial drugs
	• Patients who have received glucocorticoids, leukotriene receptor blockers, antihistamines, or anti-inflammatory drugs within the past two weeks
	• Patients with skin pathological changes at the site of the skin prick test
	• Patients who have previously participated in specific immunotherapy
	• Patients who have participated in other clinical studies in the past two months. Patients with any one of the above shall be excluded.